A major clinical study involving 3,000 patients has validated ASX-listed Proteomics’ “PromarkerD” predictive test for diabetic kidney disease with the study confirming that PromarkerD has a high probability of predicting a clinical decline in kidney function up to four years in advance of it actually happening. With the major milestone achieved, Proteomics is now looking to commercialise the technology in the USA.
15/06/2020 - 14:49
Proteomics achieves clinical validation for kidney test
By Matt Birney
15/06/2020 - 14:49
Related Data & Insights
-
Proteomics International LaboratoriesClosing price for the last 90 trading daysPowered by Morningstar ®
-
Rank Company Revenue 136th Proteomics International Laboratories $3.2m 137th Adisyn $2.9m 138th rent.com.au $2.8m 140th EVE Health Group $2.7m 141st Douugh $2.5m 200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
16 Nov 2021
Board Moves November 16, 2021
03 Nov 2021
Manufacturing grants for medical innovations
26 Oct 2021
Board Moves October 26, 2021
11 Aug 2021
Proteomics to co-develop endometriosis test
11 Jun 2021
Appointments June 11, 2021
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX